Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Potential antidiabetic strategy: synergistic effects of GPR40 agonist and DPP IV inhibitor

Feb. 26, 2014

FDA grants 3-year exclusivity to Vascepa

Feb. 24, 2014

Janssen begins phase III CREDENCE study of canagliflozin in diabetic nephropathy

Feb. 24, 2014

EMA concludes review of Protelos/Osseor

Feb. 24, 2014

EMA committee recommends approval of BioMarin's Vimizim for Morquio A syndrome

Feb. 21, 2014

Scientists at Merck & Co. divulge novel GPR40 agonists for diabetes

Feb. 21, 2014

Kyowa Hakko Kirin obtains additional approval for Regpara tablets in Japan

Feb. 21, 2014

Japan's MHLW expands approval of Hisamitsu's estradiol transdermal patch

Feb. 21, 2014

Dilafor and Lee's Pharmaceutical sign license agreement for tafoxiparin in China

Feb. 20, 2014

Zealand Pharma prepares novel glucagon receptor agonists

Feb. 20, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...